2018 Post American College of Cardiology Conference Report - ResearchAndMarkets.com

DUBLIN--()--The "2018 Post-ACC Report" report has been added to ResearchAndMarkets.com's offering.

The American College of Cardiology (ACC) 67th Scientific Session was held in Orlando, FL from 10-12 March 2018.

The highlight of this year's conference was results from Praluent's (REGN, SNY) ODYSSEY cardiovascular outcomes trial (CVOT), which were interesting to compare to Repatha's (AMGN, Astellas) FOURIER results presented at last year's conference. While the benefit on the primary endpoint was similarly modest, unlike FOURIER, there were signs of a mortality benefit, and patients with higher baseline LDL-C levels showed relatively strong results. However, the biggest news was that, in exchange for reduced barriers from US payers, the sponsors plan to negotiate net price down into a range based on a cost-effectiveness analysis for high-risk patients concurrently released by the ICER organization. We discuss the implications of these developments, including highlights from interviews with payers and comments from KOLs.

There was also updated data from AndexXa's single-arm Phase III trial ANNEXA-4, but little more information to help gauge whether the FDA will require a randomized controlled trial pre- or post-approval.

On the device front, results from VEST, the first randomized trial of Zoll's LifeVest wearable cardioverter defibrillator for prevention of sudden cardiac death, were mixed, triggering a great deal of discussion among cardiologists. Positive long-term results were also presented for HeartMate 3 (ABT), bolstering the left ventricular assist device (LVAD) in its competition against Medtronic's HeartWare HVAD.

This report also has information on Repatha and hsCRP, analyses from Ilaris's (NVS) CANTOS study, Brilinta (AZN, MDCO) after fibrinolysis, preliminary data from BC007 (Berlin Cures), an aptamer that targets autoantibodies being developed for dilated cardiomyopathy, and CoreValve (MDT) long-term data compared to surgical aortic valve replacement and from the US Pivotal Extreme Risk Study.

Key Topics Covered:

Dyslipidemia

Praluent (alirocumab; REGN, SNY) - Approved

HIGHLIGHTS FROM PAYER INTERVIEWS ON PCSK9 INHIBITORS

Evacetrapib (LLY) - Suspended

Dalcetrapib (DalCor Pharmaceuticals, RHHBY, Japan Tobacco) - Phase III

AKCEA-APOCIII-LRx (AKCA, IONS, NVS) - Phase II

Other News

Inflammatory Risk

Other News

Anticoagulation

AndexXa (andexanet alfa; PTLA) -Phase III

Heart Failure

Aironite (sodium nitrite inhalation solution; SVRA) - Suspended

Mavacamten (MYOK, SNY) - Phase II

Other News

Acute Coronary Syndrome

Other News

Peripheral Arterial Disease

JVS-100 (Juventas) - Phase II

CV Safety in Gout

Uloric (febuxostat; Takeda, ABBV, Teijin, Ipsen, Menarini, Astellas) - Approved

Devices

Wearable Defibrillation

LifeVest Wearable Cardioverter Defibrillator (ZOLL Medical) - Approved

Left Ventricular Assist Devices (LVAD)

HeartMate 3 (ABT) - Approved

Patent Foramen Ovale (PFO) Closures

Amplatzer PFO Occluder (ABT) - Approved

Transcatheter Aortic Valve Replacement (TAVR/TAVI)

CoreValve (MDT) - Approved

For more information about this report visit https://www.researchandmarkets.com/research/qf3l8p/2018_post?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Cardiology

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Cardiology